Abstract
Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases.
The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.
Keywords: Crohn's disease, inflammatory bowel disease, interleukin-13, lebrikizumab, pleiotropic, tralokinumab, ulcerative colitis.
Current Drug Targets
Title:Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside
Volume: 14 Issue: 12
Author(s): Manol Jovani, Gionata Fiorino and Silvio Danese
Affiliation:
Keywords: Crohn's disease, inflammatory bowel disease, interleukin-13, lebrikizumab, pleiotropic, tralokinumab, ulcerative colitis.
Abstract: Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases.
The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.
Export Options
About this article
Cite this article as:
Jovani Manol, Fiorino Gionata and Danese Silvio, Anti-IL-13 in Inflammatory Bowel Disease: From the Bench to the Bedside, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990170
DOI https://dx.doi.org/10.2174/13894501113149990170 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Licofelone-A Novel Analgesic and Anti-Inflammatory Agent
Current Topics in Medicinal Chemistry Drug Design of GPCR Ligands Using Physicogenetics and Chemogenomics - Principles and Case Studies
Current Topics in Medicinal Chemistry Possible Therapies of Septic Shock: Based on Animal Studies and Clinical Trials
Current Pharmaceutical Design The Therapeutic Potential of Fungal Ribotoxins
Current Pharmaceutical Biotechnology The HLA Region and Autoimmune Disease: Associations and Mechanisms of Action
Current Genomics Selected Engineering and Physicochemical Aspects of Systemic Drug Delivery by Inhalation
Current Pharmaceutical Design Current and Future Applications of Probiotics
Current Nutrition & Food Science Inhibitors of Nitric Oxide Synthase: What's up and What's Next?
Current Enzyme Inhibition From Hybrids to New Scaffolds: The Latest Medicinal Chemistry Goals in Multi-target Directed Ligands for Alzheimer’s Disease
Current Neuropharmacology Pharmacological Approaches to Targeting Muscarinic Acetylcholine Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Asthma-COPD Overlap: A more Simplistic Approach
Current Respiratory Medicine Reviews Extracellular Vesicles as Innovative Tools for Assessing Adverse Effects of Immunosuppressant Drugs
Current Medicinal Chemistry Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal The Patents on Glucocorticosteroids and Selected New Therapies for the Management of Asthma in Children: Update
Recent Patents on Inflammation & Allergy Drug Discovery Development and Validation of a Stability Indicating RP-UPLC Method for Simultaneous Determination of Rupatadine and Montelukast in Pharmaceutical Formulation
Current Pharmaceutical Analysis Potential Role of Antibiotics in the Treatment of Asthma
Current Drug Targets - Inflammation & Allergy Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
Current Enzyme Inhibition Advances in Whole Genome Sequencing Technology
Current Pharmaceutical Biotechnology Evaluation of the Anthelmentic Activity of Garlic (Allium sativum) in Mice Naturally Infected with Aspiculuris tetraptera
Recent Patents on Anti-Infective Drug Discovery Advances in Anti-inflammatory Activity, Mechanism and Therapeutic Application of Ursolic Acid
Mini-Reviews in Medicinal Chemistry